Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / AMGN
Stock rating · Biological Products, (No Diagnostic Substances)
Amgen Inc (AMGN) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Amgen Inc 67 out of 100 (Favorable). Its highest factor score is catalyst setup at 90, and its lowest is valuation at 44.
MELANY ratingRated 2026-10-07AMGN · composite score
About Amgen Inc
Amgen is a biotechnology company developing human therapeutics. Its main products include the red blood cell boosters Epogen and Aranesp, the immune boosters Neupogen and Neulasta, Enbrel and Otezla for inflammatory diseases, the bone drugs Prolia/Xgeva (approved 2010) and Evenity (2019), and its first cancer therapy Vectibix (introduced 2006). The Onyx Pharmaceuticals acquisition added the oncology drug Kyprolis.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How AMGN's rating has moved
- -1Past week, since Sep 30: score fell 1 point to 67.
- +1Past four weeks, since Sep 9: score rose 1 point to 67.
Weekly points: Sep 9: 66 · Sep 16: 67 · Sep 23: 67 · Sep 30: 68 · Oct 7: 67 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why AMGN scores 67/100
AMGN's 8 factor scores run from 44 to 90, and 4 of them sit above its composite of 67. Here is how AMGN breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 16.5x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 70%
- ROE 91%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +9%
- Earnings in 28 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 28 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How AMGN compares
As of October 7, 2026, Amgen Inc is tied for 7th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Also ranked in Healthcare Stocks. All stock rating pages.
Key risks for AMGN
- High debt-to-equity ratio 4.9x, rate-sensitive balance sheet
Sector and theme context
Amgen Inc sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds AMGN's momentum and catalyst factors above.
AMGN trade plan (Pro)
MELANY has a full position plan for Amgen Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates AMGN
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Amgen Inc's 67/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about AMGN
Is Amgen Inc (AMGN) a buy?
As of 2026-10-07, MELANY rated Amgen Inc Favorable with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Amgen Inc's MELANY score?
Amgen Inc (AMGN) has a MELANY composite score of 67/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the AMGN stock rating calculated?
MELANY scores AMGN from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Amgen Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Amgen Inc (AMGN) Favorable with a composite of 67/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the AMGN stock price forecast?
MELANY does not publish price targets or forecasts for AMGN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for Amgen Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is AMGN stock overvalued or undervalued?
MELANY's valuation factor currently reads 44/100 for Amgen Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives AMGN's read.
What price should I buy AMGN at?
Rather than chasing the current price, MELANY computes a smart entry zone for AMGN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying AMGN stock?
The top risks MELANY currently flags for Amgen Inc: High debt-to-equity ratio 4.9x, rate-sensitive balance sheet. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Amgen Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 75/100 for Amgen Inc, and earnings track record, at 84/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will AMGN stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 64/100 for AMGN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this AMGN rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores AMGN continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, AMGN included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.